To study the effect of povidone iodine gargle and nasal drops on disease transmissibility in SARS-CoV-2 infected patients

Effect of 0.5% Povidone Iodine on the Oropharyngeal/Nasopharyngeal Samples Of COVID-19 Patients: A Double-Blind Placebo-Controlled Randomized Controlled Trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/11/029063

Enrollment

Registered

2020-11-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Povidone - Iodine (PVP-I) solution: 0.5% Povidone â?? Iodine (PVP-I) solution freshly prepared by dilution of commercially available 5% PVP-I solution, in the form of nasal drops and ga

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients infected with SARS-CoV-2 on the day one of admission before administration of any routine treatment. 2. Patientsâ?? age should be 18 years and above at the time of enrollment, considering he/she can provide informed legal consent. 3. Patients presented with mild to moderate COVID-19 illness. 4. Patients presented to the hospital within 10 days of symptom onset.

Exclusion criteria

Exclusion criteria: 1. Patients infected with SARS-CoV-2 admitted in the hospital for more than one day and on routine treatment for COVID-19. 2. Any patient who has severe illness debilitating the patient to provide consent as well as adopt the study procedure. 3. Patients less than 18 years of age at the time of enrollment. 4. Patients already using oral/intra-nasal antiseptic. 5. Any patient with known thyroid disorders. 6. Pregnant and lactating women. 7. Patients who disagree to consent.

Design outcomes

Primary

Measure	Time frame
To estimate the change in the viral load and Ct value in the oropharyngeal/nasopharyngeal samples of the patients infected with SARS-CoV-2.Timepoint: 5 minutes, 3 hours and 6 hours of administration of interventional agents	—

Secondary

Measure	Time frame
The conversion of RT-PCR result in the oropharyngeal/nasopharyngeal samples of the patientsTimepoint: 5 minutes, 3 hours and 6 hours of administration of interventional agents;To determine the time duration for the sample to remain negativeTimepoint: 5 minutes, 3 hours and 6 hours of administration of interventional agents	—

Countries

India

Contacts

Public ContactDr Pranav Sharma

Uttar Pradesh University of Medical Sciences

nareshpalsingh@gmail.com9458641119

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026